TLDR: Medical affairs exists to keep scientific exchange credible and structurally separate from selling. That separation is what makes the function indispensable, and it explains why demand for MSLs, medical advisors and medical directors holds through cycles that thin other teams.
Medical affairs earns its place by keeping scientific exchange separate from selling
A pharmaceutical company holds detailed knowledge about its own products that clinicians genuinely need, and it also has an obvious commercial interest in how that knowledge is presented. Medical affairs is the organisational answer to that tension. It generates and communicates evidence under scientific rather than commercial governance, which is what allows a specialist to trust the exchange. The function’s authority rests entirely on that separation, and everything about how it is staffed and structured follows from protecting it. Read that way, the reporting lines, the incentive design and the hiring bar stop looking like corporate architecture and start looking like the load-bearing structure they are.
In practice the work spans several distinct activities. Medical affairs teams design and support evidence generation that fills gaps a registration trial left open — real-world studies, investigator-initiated research, health economic analyses — and they engage clinical experts on how a therapy performs in the patients they actually treat. They review promotional and educational materials for scientific accuracy, answer unsolicited medical enquiries through medical information channels, and feed clinical insight back into development and launch planning. Each activity carries its own compliance perimeter, which is why medical judgement is a hiring requirement rather than a preference. A perimeter can only be held by someone who understands the science well enough to see where a question has crossed it.
The separation from commercial is enforced rather than cultural, and understanding why matters for anyone considering the career. Industry codes and regulatory expectations across the EU and US restrict what a company may proactively communicate about a product, particularly outside its approved label, while allowing scientific response to a clinician’s own question. Medical affairs staff therefore operate under reporting lines, incentive structures and interaction rules deliberately insulated from sales targets. The insulation has teeth: breaches are enforceable against the company, and an interaction record is discoverable, which is why the boundary is trained, documented and audited rather than left to individual judgement. A candidate who treats the role as a scientifically credentialled route into selling misunderstands it, and interviewers screen for that misunderstanding directly.
That constraint is also where the intellectual appeal lives. Because the currency is credibility rather than persuasion, the work rewards people who are comfortable presenting unflattering data, acknowledging the limits of an evidence base, and holding a position under challenge from someone who knows the therapy area better than they do. Clinicians detect the difference immediately, since a specialist who treats the condition daily can identify an evasion faster than the person attempting it. Building a career on that footing produces a professional whose value transfers across companies and therapy areas, and the ladder reflects it.
The ladder runs from field science to functional leadership, and each rung changes the job
Medical affairs offers an unusually legible progression, but the roles differ in kind rather than only in scope. Moving up trades scientific depth in a narrow area for breadth, planning and influence over how evidence gets built — a genuine change of work, and one worth understanding before committing to the direction. The trade is real in both directions: people who loved the depth sometimes find the strategic rung abstract, while others find the field role isolating and welcome the headquarters shift. Knowing what each rung actually demands helps you judge which of them you would want to occupy for several years.
The Medical Science Liaison is the field-based scientific role and the most common entry point for people with doctoral or clinical training. MSLs build relationships with specialists and investigators in a defined territory, present data at scientific depth, respond to questions the commercial organisation may not address, and report structured insight back to headquarters. The role suits people who are energised by autonomy and by conversations with genuine experts; it demands substantial travel and a tolerance for working largely outside an office. Territory sizes vary considerably between countries, and that variation matters more to daily life than the job description suggests, since a compact national territory produces day trips while a regional one produces weeks away.
The Medical Advisor or Medical Manager sits at headquarters and owns medical strategy for a product or therapy area. The work involves designing the evidence plan, deciding which studies to support, reviewing materials, and partnering with regulatory, market access and commercial colleagues on launch planning. Influence replaces territory as the operating currency: an advisor rarely controls the budgets or teams involved, so the role rewards people who can hold a scientific position inside a cross-functional argument. The pressure in those rooms is real, because a study that strengthens the evidence base competes for the same budget as activity with a faster commercial return. Many MSLs move here when they want to shape the strategy they have been executing.
Above that, the Medical Director or Head of Medical Affairs leads the function, sets its strategy, carries responsibility for its compliance posture, and sits close to the top of both the scientific and commercial organisation. Adjacent specialisms — medical writing, medical information, health economics and outcomes research, and the pharmacovigilance interface — run alongside the ladder and offer lateral moves that broaden a profile without leaving the discipline. Those moves are worth planning rather than accepting opportunistically, since a spell in medical information or writing supplies exactly the source discipline a director role later depends on. HEOR in particular has grown in importance as payers have become the decisive audience.
| Role | Where the work happens | What it demands |
|---|---|---|
| Medical Science Liaison | Field, within a defined territory | Scientific depth, credibility with specialists, autonomy, travel |
| Medical Advisor / Manager | Headquarters, product or therapy area | Evidence planning and influence across functions without direct authority |
| Medical Director / Head of Medical Affairs | Functional leadership | Strategy, compliance ownership, team building, executive presence |
| Medical writing and medical information | Headquarters or outsourced provider | Precision, source discipline, high output under review |
| HEOR | Headquarters, payer-facing | Health economics, modelling, evidence for reimbursement decisions |
Demand holds because evidence complexity and payer scrutiny are both rising
Two forces sustain hiring in this function independently of the wider cycle, and they reinforce each other rather than operating separately. Therapies have become substantially harder to explain, and the audiences deciding whether to fund and use them have become harder to satisfy. Both trends increase the volume of credible scientific communication a single product requires, which means the workload per launch grows even when the number of launches does not. Portfolio decisions therefore affect this function differently from commercial teams, since a company narrowing its pipeline still owes the same explanatory work on every asset it keeps. Neither trend shows any sign of reversing, and that is what makes the demand structural rather than cyclical.
Scientific complexity is the first force. Cell and gene therapies, bispecific antibodies, biomarker-selected indications and companion diagnostics carry mechanisms and evidence packages that a busy clinician cannot absorb from a data sheet. Conditional approvals and adaptive pathways compound this by placing products in practice while evidence is still maturing, which creates a genuine ongoing need for people who can explain what is known, what remains uncertain, and how the two are being resolved. A companion diagnostic adds a further layer, since the therapy and the test travel together and a prescriber has to understand both. Companies filing with the European Medicines Agency and the United States Food and Drug Administration build medical teams around exactly that explanatory burden.
Payer scrutiny is the second and has changed the function’s centre of gravity. Regulatory approval no longer determines commercial outcome in most European markets, where health technology assessment bodies and national payers decide reimbursement on comparative effectiveness and cost. That shifts a substantial evidence burden onto medical affairs, since the studies payers want frequently differ from those regulators required. The divergence is structural: a regulator asks whether a therapy works against a control, while an assessor asks whether it works better than whatever the health system already pays for. Professionals who can operate in both registers — designing evidence that satisfies an assessor and a health economist — are notably scarce, and this is where the function’s strongest pay progression sits.
Supply has not kept pace with either force. Analysis of the Swiss market in 2026 identifies persistent shortages across scientific and regulatory functions, and medical affairs sits squarely inside that gap because its entry requirements are high and its skills take years of therapy-area exposure to build. The bottleneck resists the usual remedies, since a company can fund training but cannot compress the time a specialist needs to become credible with other specialists. Compensation follows scarcity, with the clearest premiums attaching to specialised therapy areas and to the seniority where scientific and commercial judgement combine. What that scarcity rewards is worth being precise about.
Credibility with clinicians is the actual product, and it is built on judgement
The measurable outputs of a medical affairs role — meetings held, materials reviewed, insights logged — are proxies for something that resists measurement entirely. What the function actually produces is the willingness of expert clinicians to take a company’s scientific communication seriously, and that willingness accumulates slowly and can be lost in a single overstated claim. The asymmetry is what makes the work demanding, since years of careful exchange are weighed against one conversation where a professional claimed more than the data supported. Every skill that raises your market value in this discipline traces back to building and protecting it. Employers interview accordingly, probing how a candidate handles the moments where credibility is genuinely at stake.
Scientific grounding is the entry condition, and it is usually evidenced by a PhD, PharmD, MD or equivalent clinical training, though relevant depth acquired another way is accepted by many employers. The credential matters less as a qualification than as proof that you have generated evidence yourself and therefore understand how it can be wrong. Someone who has watched a hypothesis fail, argued about a statistical plan or defended a result at review carries an instinct for the limits of data that reading alone never supplies. A specialist recognises the difference between someone who has read a trial and someone who has run one within a few minutes of conversation. That recognition is what opens the relationship on which everything else depends.
Translation is the skill that turns grounding into performance. The job requires moving between a detailed statistical discussion with an investigator, a concise briefing for a commercial team, and a written response that survives compliance review — each demanding a different register while preserving the same underlying accuracy. Simplification that quietly overstates a finding destroys the credibility the function exists to protect, which is why precision under compression is the specific competence employers probe. The discipline is learnable and shows in small choices: naming the population a result applies to, keeping a confidence interval attached to an estimate, distinguishing an observed association from a demonstrated effect. Candidates should prepare to explain a complex result at two levels of depth on request.
Two further capabilities increasingly separate candidates. Compliance fluency lets a professional navigate the boundary between scientific exchange and promotion without escalating every question, which makes them faster and more trusted than a colleague of equal scientific ability. The value is practical rather than theoretical, since a clinician asking about an off-label use expects an answer in the room and a professional who knows what may be said gives one. Comfort with data and omnichannel engagement matters as clinician interaction moves across digital channels and as insight is expected to arrive structured rather than anecdotal. Both are learnable, which is encouraging for anyone planning an entry.
Breaking in means converting scientific depth into demonstrated therapy-area fluency
The most common entry is a direct move from a PhD or clinical post into an MSL role, and it succeeds when the candidate can show relevance rather than only excellence. Employers hire for a specific therapy area because the role requires holding a conversation with a specialist on their own ground, so a distinguished academic record in an unrelated field competes poorly against solid, current work in the right one. This surprises strong researchers, who reasonably expect scientific calibre to travel. The mismatch comes from what the employer is buying: credibility in one room with one community, which is a narrower and more specific asset than general research ability. Establishing therapy-area alignment is therefore the practical task facing most people making this move.
Alignment can be constructed deliberately from outside the industry. Reading the pivotal trials in a target therapy area until you can discuss their design and limitations, attending the congresses where that community gathers, and building relationships with clinicians already working in it all generate genuine fluency within months. A candidate who can discuss the competitive evidence landscape of a therapy area in an interview demonstrates the exact behaviour the role requires, which is a far stronger signal than a general claim of scientific ability. The interview and the job are the same activity in this respect, which is why preparation of this kind converts so reliably. Publication in the area helps considerably where it exists.
Lateral entry from inside the industry follows a different logic and is often faster. Clinical operations, medical writing, regulatory affairs and medical information all supply candidates who already understand how a regulated organisation works, and that knowledge removes a substantial part of the onboarding risk an employer carries. Knowing how a document moves through review, why an approval step exists and what an inspector looks for saves months that a brilliant external hire spends learning. People arriving this way usually need to demonstrate the external-facing dimension instead — presenting at internal scientific meetings, supporting an advisory board, or accompanying an MSL in the field builds the evidence hiring managers look for.
Progression beyond the field role rewards a different kind of preparation from the one that got you there. The step from MSL to advisor and onward to director shifts the work towards strategy, budget stewardship and cross-functional influence, and the scientific excellence that made someone an outstanding field professional carries them only part of the way. Structured leadership development shortens that transition materially, because it supplies the commercial and organisational vocabulary the next role assumes. Acquiring it before the promotion rather than during it also protects the first months in the new seat, when credibility with a new set of colleagues is being established. Edward Galle candidates can use our HBR-backed training journeys to build that judgement ahead of the move rather than during it.
Edward Galle recruits medical affairs and life-sciences professionals for employers across Switzerland, the EU and the US. Submit your CV for a confidential review, or tell our team which therapy area you want to build in.
References
- Panda International. Swiss Life Sciences Hiring Trends for 2026. https://www.panda-int.com/en-ch/insights/swiss-life-sciences-hiring-trends-for-2026/
- European Medicines Agency. https://www.ema.europa.eu/en
- U.S. Food and Drug Administration. https://www.fda.gov/
